alleles in various strain backgrounds. The KpnI-SacII fragment from pMPG2S (23) was used 173 to integrate a P MDR1 -GFP reporter fusion at the ACT1 locus of different strains (see Table S1 ). 174
The SacI-ApaI fragments from pZCF36H2 and pZCF36H3 were used for expression of 175 3xHA-tagged wild-type MRR1 and MRR1 P683S alleles, respectively, from the MRR1 promoter 176 in mrr1∆ mutants of strain SC5314 and in the reporter strain CAG48MRR1M4B. The ApaI-177
SacII fragments from pZCF36EH2 and pZCF36EH3 served to express these HA-tagged 178 MRR1 alleles from the ADH1 promoter in the same strains. The ApaI-SacII fragment from 179 pZCF36EH3 was also used to express the 3xHA-tagged MRR1
P683S allele under control of the 180 ADH1 promoter in mrr1∆ cap1∆ mutants of strain SC5314. Selection of nourseothricin-181 resistant transformants was performed as described previously (25) and the correct integration 182 of each construct was confirmed by Southern hybridization with gene-specific probes. 183
Isolation of genomic DNA and Southern hybridization 184
Genomic DNA from C. albicans was isolated as described previously (25), digested with 185 appropriate restriction enzymes, separated on a 1% agarose gel and, after ethidium bromide 186 staining, transferred by vacuum blotting onto a nylon membrane and fixed by UV cross-187 linking. Southern hybridization with enhanced chemiluminescence-labeled probes was 188 performed with the Amersham ECL TM Direct Nucleic Acid Labelling and Detection System 189 (GE Healthcare, Braunschweig, Germany) according to the instructions of the manufacturer. 190
FACS analysis 191
Fluorescence-activated cell sorter (FACS) analysis was performed with a FACSCalibur 192 cytometry system equipped with an argon laser emitting at 488 nm (Becton Dickinson, 193 9 using logarithmic amplifiers. The mean fluorescence values were determined with CellQuest
Drug susceptibility tests 199
Stock solutions of the drugs were prepared as follows. Fluconazole (5 mg/ml) was dissolved 200 in water and cerulenin (5 mg/ml) was dissolved in dimethylsulfoxide (DMSO). In the assays, 201 serial twofold dilutions in the assay medium were prepared from an initial concentration of 202 100 µg/ml of each drug. Susceptibility tests were carried out in high resolution medium 203 (14.67 g HR-Medium [Oxoid GmbH, Wesel, Germany], 1 g NaHCO 3 , 0.2 M phosphate 204 buffer [pH 7.2]), using a previously described microdilution method (28). 205
Transcription profiling 206
Gene expression profiles were obtained by hybridizing labeled cRNAs generated from 207 C. albicans total RNA onto Affymetrix C. albicans custom expression arrays (CAN07, 49-208 5241 array format) described elsewhere (11). Total RNA was isolated using the hot sodium 209 dodecyl sulfate-phenol method and subsequent cRNA synthesis and labeling was performed 210 as previously described (11). 211
The cRNA pellet was suspended in 10 µl of RNase-free water, and 10 µg was fragmented by 212 ion-mediated hydrolysis at 95°C for 35 min in 200 mM Tris-acetate (pH 8.1), 500 mM 213 potassium acetate, 150 mM magnesium acetate. The fragmented cRNA was hybridized for 214 16 h at 45°C to the C. albicans Affymetrix expression arrays. Arrays were washed at 25°C 215 with 6x SSPE (1x SSPE is 0.18 M NaCl, 10 mM NaH2PO4, and 1 mM EDTA [pH 7.7]), 216 0.01% Tween 20, followed by a stringent wash at 50°C with 100 mM MES [2-(N-217 morpholino)ethanesulfonic acid], 0.1 M NaCl, 0.01% Tween 20. Hybridizations and washes 218 employed the Affymetrix Fluidics station 450 using their standard EukGE-WS2v5 protocol. 219
The arrays were then stained with phycoerythrin-conjugated streptavidin (Molecular Probes), 220 and the fluorescence intensities were determined using the GCS 3000 high-resolution 221 applied to the data. The parameters used were as follows: a window size of 400 bp, a 283 maximum genomic distance of 60 bp, and a minimum length of 120 bp. The replicate data 284 were combined, and peak finding (i.e., determining the Mrr1 binding sites) was done using a 285 pseudomedian signal threshold of at least twofold and p-value cut-off of 0.01. 286
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The role of Upc2 in MDR1 expression and Mdr1-mediated drug resistance 288
To investigate the capacity of a constitutively active Upc2 to induce MDR1 expression, we 289 integrated a P MDR1 -GFP reporter fusion into derivatives of strain SC5314 in which one or both 290 endogenous UPC2 alleles had been replaced by the hyperactive UPC2 G648D allele. The 291 fluorescence of the cells was quantified by FACS analysis. MDR1 is not detectably expressed 292 in the wild-type strain SC5314 under standard growth conditions and transformants of this 293 strain exhibited only background fluorescence (Fig. 1, bar pair 1 ). The fluorescence of 294 reporter strains that were homozygous for the UPC2 G648D allele was increased about 2.5-fold 295 over background, confirming that this hyperactive UPC2 allele can activate MDR1 expression 296 (Fig. 1, bar pair 5) . However, the Upc2-mediated MDR1 induction was negligible compared 297 to the strong activation of MDR1 expression by the hyperactive MRR1 P683S allele, especially 298 when the P683S gain-of-function mutation was present in both MRR1 alleles (Fig. 1 , bar pairs 299 8 and 9). In addition, while induction of the MDR1 promoter by the hyperactive UPC2 allele 300 required the presence of MRR1 (Fig. 1, bar pairs 4-7) , the MRR1 P683S allele activated the 301 MDR1 promoter with equal efficiency in the presence or absence of a functional UPC2 gene 302 (Fig. 1, bar pairs 8-11 ). These results demonstrate that Upc2 plays only a minor role in MDR1 303 expression and Mrr1 is a more important regulator of this efflux pump. 304
To evaluate the effect of the hyperactive UPC2 G648D allele on drug resistance in the presence 305 and absence of MRR1, we tested the susceptibilities of the strains to fluconazole and cerulenin 306 (Table 1) . As previously reported (12), strains that carried the G648D mutation in both UPC2 307 alleles exhibited an 8-fold increased resistance to fluconazole compared to the wild-type 308 parental strain (MIC increased from 0.2 µg/ml to 1.56 µg/ml), and the same increase was also 309 observed in an mrr1∆ background. In contrast, the UPC2 G648D allele did not confer increased 310 resistance to cerulenin, which is a substrate of the Mdr1 efflux pump, even in the presence ofthe UPC2 G648D allele was caused by the upregulation of ERG11 and other Upc2 target genes, 313 but not by increased MDR1 expression. On the other hand, the hyperactive MRR1 P683S allele 314 caused a 16-fold increased resistance to cerulenin (MIC increased from 0.39 µg/ml to 315 6.25 µg/ml) in the presence or absence of UPC2, in line with its ability to activate the MDR1 316 promoter in both wild-type and upc2∆ strains. As previously reported (11), the upc2∆ mutants 317 were hypersusceptible to fluconazole. Nevertheless, the P683S mutation in MRR1 caused a 318 16-fold increase in fluconazole resistance also in the upc2∆ mutants when present in both 319 MRR1 alleles (MIC increased from 0.05 µg/ml to 0.78 µg/ml), similar to its effect in a wild-320 type background. These results demonstrate that a hyperactive Mrr1 confers increased drug 321 resistance independently of Upc2. 322
The role of Cap1 in MDR1 expression and Mdr1-mediated drug resistance 323 A C-terminally truncated CAP1 allele has been shown to cause constitutive MDR1 324 upregulation and increased fluconazole resistance (1) . To investigate if MDR1 activation by a 325 hyperactive CAP1 allele requires MRR1, we replaced one or both wild-type CAP1 alleles with 326 a C-terminally truncated CAP1 allele (CAP1 ∆C333 ) in the wild-type strain SC5314 as well as in 327 mutants lacking MRR1. The activity of the MDR1 promoter was monitored using a P MDR1 -328 GFP reporter fusion. MDR1 expression was especially pronounced when the C-terminal 329 truncation was present in both CAP1 alleles (Fig. 2, bar pairs 5) . MDR1 activation by the 330
CAP1
∆C333 allele was also observed in the mrr1∆ mutants, albeit at a reduced level compared 331 to that in the wild-type background, demonstrating that the induction of the MDR1 promoter 332 by the hyperactive CAP1 ∆C333 allele was partially Mrr1-independent (Fig. 2 , bar pairs 4-7). 333
However, the MRR1 P683S allele caused a stronger MDR1 activation than the CAP1 ∆C333 allele. 334
We also compared the effect of hyperactive CAP1 and MRR1 alleles on drug resistance in the 338 different strain backgrounds (Table 2 ). An increased resistance to the Mdr1 substrate 339 cerulenin was only observed when the hyperactive CAP1 ∆C333 allele was substituted for both 340 endogenous CAP1 wild-type alleles. In contrast, a reproducibly increased resistance to 341 fluconazole was seen already in the heterozygous strains. Fluconazole resistance was further 342 elevated in strains that were homozygous for the CAP1 ∆C333 allele, but only in the presence of 343
MRR1. Similar to its ability to activate the MDR1 promoter in a CAP1-independent fashion, 344 the hyperactive MRR1 P683S allele did not require the presence of an intact CAP1 gene to 345 mediate resistance to fluconazole and cerulenin. These data show that hyperactive CAP1 and 346
MRR1 alleles can independently confer increased drug resistance. 347
Cooperation between Mrr1 and Cap1 in MDR1 expression 348
As hyperactive MRR1 and CAP1 alleles are each able to activate the MDR1 promoter, we 349 investigated whether the presence of both types of activated transcription factors would have 350 an additive or even synergistic effect on the expression of the efflux pump. For this purpose, 351 the two wild-type CAP1 alleles were replaced by the CAP1 ∆C333 allele in strains that were 352 homozygous for the MRR1 P683S allele. The activity of the MDR1 promoter in these strains was 353 compared with that in strains containing only the MRR1 P683S or CAP1 ∆C333 alleles using the 354 P MDR1 -GFP reporter fusion. As can be seen in MDR1 upregulation in response to these inducers, we quantified the activity of the MDR1 364 promoter in the presence or absence of benomyl and H 2 O 2 in wild-type and mutant strains 365 carrying a P MDR1 -GFP reporter fusion (Fig. 4) . As reported previously (23), the induction of 366 the MDR1 promoter was abolished in mrr1∆ mutants. Deletion of UPC2 had no effect on the 367 inducibility of the MDR1 promoter, whereas MDR1 expression in response to benomyl was 368 reduced and no MDR1 induction by H 2 O 2 was observed in the cap1∆ mutants under the 369 experimental conditions used. These results demonstrate that Upc2 is not required for MDR1 370 induction in response to these chemicals, whereas Cap1 is required for H 2 O 2 -induced MDR1 371 expression and contributes to its induction by benomyl, and Mrr1 is essential for MDR1 372 upregulation by both inducers. 373
Contribution of the Mdr1 efflux pump to Mrr1-, Upc2-, and Cap1-mediated drug 374 resistance 375
In order to evaluate the importance of the Mdr1 efflux pump for drug resistance conferred by 376 hyperactive Mrr1, Upc2, and Cap1, we introduced the MRR1
P683S
, UPC2
G648D
, and CAP1 ∆C333 377 alleles into mdr1∆ mutants generated from strain SC5314 (see Experimental procedures and 378 Table S1 ). As can be seen in Table 3 , the increased fluconazole resistance conferred by the 379 hyperactive Mrr1 was reduced, but not abolished in cells lacking the Mdr1 efflux pump (from 380 16-fold in the wild type to four-to eightfold in mdr1∆ mutants), demonstrating that other 381
Mrr1 target genes contribute to the fluconazole-resistant phenotype of strains containing gain-382 of-function mutations in this transcription factor. On the other hand, the Mrr1-mediated 383 cerulenin resistance seen in a wild-type background was largely abrogated in mdr1∆ mutants 384 exclusively, by the Mdr1 efflux pump. The increased fluconazole resistance caused by the 386 hyperactive CAP1
∆C333 allele was reduced from fourfold to twofold in the absence of MDR1, 387 whereas the moderate cerulenin resistance conferred by this allele depended on a functional 388 Mdr1 efflux pump. In contrast, the increased fluconazole resistance conferred by the 389 hyperactive Upc2 did not depend on the presence of a functional MDR1 gene, confirming that 390
Upc2-mediated azole resistance is caused by upregulation of the ERG and possibly other 391
Upc2 target genes. 392
Comparison of the gene expression profiles of wild type and cap1∆ mutants 393 expressing a hyperactive MRR1 allele 394
The results shown above demonstrate that overexpression of the Mdr1 efflux pump 395 contributes only partially to the fluconazole resistance conferred by activated MRR1 and 396 CAP1 alleles. Mrr1 and Cap1 share some of their target genes (23, 39). In order to evaluate 397 whether a hyperactive Mrr1 can activate all its target genes independently of Cap1, we 398 compared the global gene expression patterns of strains containing the P683S gain-of-399 function mutation in both MRR1 alleles in wild-type and cap1∆ backgrounds. In a previous 400 study, we found 19 genes to be significantly upregulated in strains expressing one copy of the 401
MRR1
P683S allele (23). In line with the stronger effect of two copies of the MRR1 P683S allele on 402 MDR1 expression (see Figs. 1 and 2 ), a higher number of genes (83) were reproducibly 403 upregulated in two independently constructed strains that were homozygous for the P683S 404 mutation (Table S2 ). For 67 of these 83 genes we obtained reliable hybridization signals in 405 both experiments with the cap1∆ mutants. Twenty five of the 67 genes were also reproducibly 406 upregulated, while 27 were not significantly (< 2-fold) upregulated in the cap1∆ mutants. has also been observed for Upc2 (41) and is likely to be caused by unmasking of an activation 427 domain. When the same proteins were expressed in mrr1∆ mutants of strain SC5314, the 428 presence of the HA tag also resulted in increased fluconazole resistance, confirming the 429 activation of wild-type Mrr1 by the HA tag (Table 4) . 430
In order to achieve a similar Mrr1 activity as in strains that are homozygous for a hyperactive 431 absence of Cap1, the HA-tagged MRR1 P683S allele was also expressed from the ADH1 440 promoter in mrr1∆ cap1∆ double mutants. Western blot analysis showed that the HA-tagged 441
Mrr1
P683S protein was expressed at comparable levels in independent transformants of the 442 mrr1∆ single and mrr1∆ cap1∆ double mutants (Fig. 5B) . Therefore, one clone was used for 443 the ChIP-chip experiments in each case, and a strain that expressed the untagged MRR1 P683S 444 allele in the mrr1∆ background served as the reference. 445
Using the criteria described in the experimental procedures, we identified 710 Mrr1 binding 446 sites in the wild-type strain, 608 of which were also found in the cap1∆ mutant (Table S3) . (Table S3) . Therefore, 40 454 of the 83 upregulated genes seem to be direct targets of Mrr1, including the MDR1 efflux 455 pump and MRR1 itself, whereas the downregulation of genes seems to be an indirect effect 456 (Table S2) . Table 5 lists all genes that were both upregulated and bound by the hyperactive 457

P683S
. Almost all of these (37/40) were also bound by Mrr1 in the absence of Cap1 and 458 the majority of them (22/40) were upregulated in a Cap1-independent fashion, while only 459 seven of these 40 genes were reproducibly not upregulated (<2-fold in both experiments) in 460 the cap1∆ mutants, despite being bound by Mrr1. (1, 11, 19, 26-27, 31, 39, 41) . Here, we studied the role of two of these 495 transcription factors, Upc2 and Cap1, for which gain-of-function mutations have been 496 described that render them hyperactive (1, (11) (12) . 497
Upc2 binds to the MDR1 promoter and modulates MDR1 expression in response to 498 environmental conditions in C. albicans wild-type strains (41). We found that Upc2 is not 499 required for upregulation of MDR1 by benomyl and hydrogen peroxide, two chemicals that 500 are commonly used to induce expression of this efflux pump (16, 23, 27). To date, only three 501 gain-of-function mutations that render Upc2 hyperactive have been found in fluconazole-502 resistant, clinical C. albicans isolates. Of these, the G648D mutation has a stronger effect on 503 ERG11 overexpression and fluconazole resistance than the A643T and A643V mutations (11-504 12, 14). However, even when present in both UPC2 alleles, the G648D mutation caused only 505 a moderate MDR1 upregulation that did not contribute to drug resistance. This result suggests 506 that gain-of-function mutations in Upc2 are unlikely to be a cause of Mdr1-mediated drug 507 resistance in C. albicans. 508
In contrast to Upc2, Cap1 was essential for MDR1 upregulation in the presence of hydrogen 509 peroxide and also contributed to MDR1 induction by benomyl. The former result confirms 510 earlier observations showing the requirement of Cap1 for hydrogen peroxide-induced MDR1 511 expression (27). Conflicting results were reported with respect to the involvement of Cap1 inbenomyl-induced MDR1 expression (27), while in another study MDR1 transcript levels in 514 response to benomyl were found to be fourfold reduced in a cap1∆ mutant compared to a 515 wild-type control strain (39). In line with the latter results, we found that full activation of the 516 MDR1 promoter by benomyl depended on Cap1 (see Fig. 4 ). As Mrr1 is essential for MDR1 517 upregulation in response to both inducing chemicals, Mrr1 cooperates with Cap1, but not 518 Upc2, to mediate MDR1 induction by these environmental stimuli. target genes to fluconazole resistance was even higher than that of MDR1, as is evident from 542 the still four-to eightfold increase in the MIC of strains expressing the hyperactive Mrr1 in an 543 mdr1∆ background compared to the 16-fold increase in the parental wild-type background 544 (Table 3 ). It is currently not known which of these genes are involved in Mrr1-mediated 545 fluconazole resistance. As the drug resistance conferred by the hyperactive Mrr1 did not 546 depend on the presence of CAP1 (Table 2) , the most likely candidates are those genes that are 547 upregulated by Mrr1 in a Cap1-independent fashion. As noted previously (23), many Mrr1 548 target genes encode putative oxidoreductases which may act to remedy fluconazole-induced 549 cell damage (see Table 5 ). strains were used (see Table S1 ): SCMPG2A and -B (wild type), SCMRR1M4MPG2A strains were used (see Table S1 ): SCMPG2A and -B (wild type), SCMRR1M4MPG2A deviations from three experiments). The following strains were used (see Table S1 were used (see Table S1 ): SCMPG2A and -B (wild type), SCMRR1M4MPG2A and -B 790 
